This activity is jointly provided by Postgraduate Institute for Medicine, DKBmed, LLC, and the Institute for Johns Hopkins Nursing (IJHN). This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)™
Nurses — 0.5 Contact Hours
This activity is intended for clinicians treating patients in underserved populations.
After completing this activity, the participant should be better able to:
- Evaluate the safety, efficacy, and clinical trial results of pharmacologic treatments for hospitalized patients with COVID-19.
- Determine the safety, efficacy, and clinical trial results of supportive care treatments for managing patients with severe and critical COVID-19
Dinora Chinchilla, MD
Health Sciences Assistant Clinical Professor
UC Irvine Department of Pulmonary Critical Care
UC Irvine School of Medicine
Kathleen Bailey, NP
Acute Care Practice Nurse Practitioner
The Johns Hopkins Hospital
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) and IJHN require faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM and IJHN policy. PIM and IJHN are committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Dinora Chinchilla, MD
Kathleen Bailey, NP
The PIM and IJHN planners and others have nothing to disclose. The DKBmed planners and others have nothing to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, DKBMed and the Institute for Johns Hopkins Nursing (IJHN). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
- Certificates will be available for print or download.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.